• Initial computational analysis demonstrated that Evaxion's AI-Immunology™ platform can identify novel vaccine targets to combat Group A Streptococcus (GAS)
• New vaccine program is added to Evaxion's pipeline under the name EVX-B4
• Urgent need for preventive measures against GAS underscores the significant medical and commercial potential of EVX-B4
• Addition of a novel infectious disease candidate to the pipeline is in line with Evaxion's partnership strategy

COPENHAGEN, Denmark, June 25, 2025 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, initiates work to develop a new preventive vaccine against Group A Streptococcus (GAS), a bacteria causing hundreds of millions of infections globally each year. Infection carries the risk of several complications including life threatening conditions like rheumatic heart disease and necrotizing fasciitis ("flesh eating bacteria") and less severe yet serious diseases like strep throat and scarlet fever.

The new vaccine program, named EVX-B4, has been added to Evaxion's research & development (R&D) pipeline of cancer and infectious disease vaccine candidates. Initial computational analysis demonstrated that AI-Immunology™ can identify novel vaccine targets to combat GAS, which could pave the way for a new approach to fight the bacteria. Deploying AI-Immunology™ allows for fast and effective target discovery, design and validation, accelerating preclinical development of EVX-B4. This work will create a comprehensive preclinical data package to facilitate partnership discussions.

Adding EVX-B4 to the pipeline achieves another of Evaxion's milestones for 2025. Evaxion's R&D pipeline now comprises five specified vaccine candidates for infectious diseases and three for cancer. The build-up of the pipeline supports Evaxion's partnership strategy as we increase the number of assets for out-licensing.